Stock Track | IGM Biosciences Soars After Bullish Analyst Actions

Stock Track11-11

Shares of IGM Biosciences (IGMS) surged 5.53% on November 11th, following bullish actions from Wall Street analysts. The biopharmaceutical company's stock gained momentum after RBC Capital and Stifel both reiterated their "Buy" ratings and increased their price targets for the stock.

RBC Capital analyst Brian Abrahams maintained a "Buy" rating on IGM Biosciences, citing the company's promising pipeline and potential for future growth. Abrahams did not disclose a specific price target in the report released on November 8th.

Meanwhile, Stifel analyst raised the firm's price target on IGM Biosciences to $27 from $25, while keeping a "Buy" rating. The firm expressed confidence in the company's management and their plans for advancing the development of their oncology treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152914755?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152914755","market":"hk","top_or_hot":-1,"title":"Stock Track | IGM Biosciences Soars After Bullish Analyst Actions","media":"Stock Track","content":"<p>Shares of IGM Biosciences (IGMS) surged 5.53% on November 11th, following bullish actions from Wall Street analysts. The biopharmaceutical company's stock gained momentum after RBC Capital and Stifel both reiterated their \"Buy\" ratings and increased their price targets for the stock.</p>\n\n<p>RBC Capital analyst Brian Abrahams maintained a \"Buy\" rating on IGM Biosciences, citing the company's promising pipeline and potential for future growth. Abrahams did not disclose a specific price target in the report released on November 8th.</p>\n\n<p>Meanwhile, Stifel analyst raised the firm's price target on IGM Biosciences to $27 from $25, while keeping a \"Buy\" rating. The firm expressed confidence in the company's management and their plans for advancing the development of their oncology treatments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | IGM Biosciences Soars After Bullish Analyst Actions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | IGM Biosciences Soars After Bullish Analyst Actions\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-11 22:39 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of IGM Biosciences (IGMS) surged 5.53% on November 11th, following bullish actions from Wall Street analysts. The biopharmaceutical company's stock gained momentum after RBC Capital and Stifel ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IGMS","symbol_name":"IGM Biosciences","start_time":0,"source_url":"","article_id":"1152914755","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152914755","pubTimestamp":1731335970,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of IGM Biosciences  surged 5.53% on November 11th, following bullish actions from Wall Street analysts. The biopharmaceutical company's stock gained momentum after RBC Capital and Stifel both reiterated their \"Buy\" ratings and increased their price targets for the stock.RBC Capital analyst Brian Abrahams maintained a \"Buy\" rating on IGM Biosciences, citing the company's promising pipeline and potential for future growth. Abrahams did not disclose a specific price target in the report rele","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IGMS":"IGM Biosciences"},"translate_title":"分析师看涨行动后，IGM Biosciences股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IGMS":1},"content_text":"Shares of IGM Biosciences (IGMS) surged 5.53% on November 11th, following bullish actions from Wall Street analysts. The biopharmaceutical company's stock gained momentum after RBC Capital and Stifel both reiterated their \"Buy\" ratings and increased their price targets for the stock.\nRBC Capital analyst Brian Abrahams maintained a \"Buy\" rating on IGM Biosciences, citing the company's promising pipeline and potential for future growth. Abrahams did not disclose a specific price target in the report released on November 8th.\nMeanwhile, Stifel analyst raised the firm's price target on IGM Biosciences to $27 from $25, while keeping a \"Buy\" rating. The firm expressed confidence in the company's management and their plans for advancing the development of their oncology treatments.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152914755"}